GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (NAS:GTBP) » Definitions » Cyclically Adjusted FCF per Share

GTBP (GT Biopharma) Cyclically Adjusted FCF per Share : $-219.19 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GT Biopharma Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

GT Biopharma's adjusted free cash flow per share for the three months ended in Dec. 2024 was $-1.093. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-219.19 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of GT Biopharma was 32.50% per year. The lowest was 10.40% per year. And the median was 15.20% per year.

As of today (2025-05-11), GT Biopharma's current stock price is $2.27. GT Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $-219.19. GT Biopharma's Cyclically Adjusted Price-to-FCF of today is .


GT Biopharma Cyclically Adjusted FCF per Share Historical Data

The historical data trend for GT Biopharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GT Biopharma Cyclically Adjusted FCF per Share Chart

GT Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -351.39 -304.52 -272.52 -242.43 -219.19

GT Biopharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -242.43 -238.75 -232.43 -225.90 -219.19

Competitive Comparison of GT Biopharma's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, GT Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Cyclically Adjusted Price-to-FCF falls into.


;
;

GT Biopharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GT Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-1.093/133.1571*133.1571
=-1.093

Current CPI (Dec. 2024) = 133.1571.

GT Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 -650.000 102.862 -841.438
201706 -391.000 103.349 -503.772
201709 -72.161 104.136 -92.272
201712 -21.959 104.011 -28.112
201803 -43.143 105.290 -54.562
201806 -18.102 106.317 -22.672
201809 -35.051 106.507 -43.822
201812 -12.889 105.998 -16.191
201903 -9.610 107.251 -11.931
201906 -10.657 108.070 -13.131
201909 -9.791 108.329 -12.035
201912 -3.540 108.420 -4.348
202003 -1.628 108.902 -1.991
202006 -24.191 108.767 -29.616
202009 -11.340 109.815 -13.750
202012 -11.075 109.897 -13.419
202103 -6.810 111.754 -8.114
202106 -3.839 114.631 -4.459
202109 -3.756 115.734 -4.321
202112 -3.194 117.630 -3.616
202203 -4.815 121.301 -5.286
202206 -2.676 125.017 -2.850
202209 -2.790 125.227 -2.967
202212 -3.838 125.222 -4.081
202303 -2.683 127.348 -2.805
202306 -1.445 128.729 -1.495
202309 -1.437 129.860 -1.473
202312 -1.482 129.419 -1.525
202403 -3.014 131.776 -3.046
202406 -2.065 132.554 -2.074
202409 -1.225 133.029 -1.226
202412 -1.093 133.157 -1.093

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


GT Biopharma  (NAS:GTBP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


GT Biopharma Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of GT Biopharma's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GT Biopharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Executives
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Michael Martin Breen director, officer: Exec. Chair. and Interim CEO LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU
Manu Ohri officer: CFO & Secretary 2355 MAIN STREET, SUITE 120, IRVINE CA 92614
Bruce Wendel director 70 ELEVEN O'CLOCK ROAD, WESTON CT 06883
Gregory Berk officer: Pres. of R&D, CMO HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Alan Louis Urban director 1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404
Gavin Choy officer: Acting Chief Financial Officer 8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005
Steven W Weldon director, officer: CFO 7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835
Shawn Cross director, officer: Chief Executive Officer 1825 K STREET SUITE 510, WASHINGTON DC 20006
Raymond W. Urbanski officer: Chief Medical Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Kathleen Clarence-smith director, 10 percent owner, officer: CEO 1623 31ST STREET NW, WASHINGTON DC 20007
Mark J Silverman 10 percent owner 224 22ND ST., SANTA MONICA CA 90402
Bristol Capital Llc 10 percent owner
Bristol Investment Fund Ltd 10 percent owner 89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205